Bayer, Merck's Verquvo gets approval in China to treat certain patients with heart failure

May 19, 2022 5:08 AM ETBayer Aktiengesellschaft (BAYRY), BAYZFMRKBy: Ravikash, SA News Editor

Businessman stamping approved stamp on document in meeting

BrianAJackson/iStock via Getty Images

  • China's National Medical Products Administration approved Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) and Merck's (MRK) Verquvo to treat certain patients with heart failure (HF).
  • Verquvo (vericiguat) can now be used in China to reduce the risk of HF hospitalization or requiring intravenous (IV) diuretics in emergency, in adults with symptomatic chronic HF and reduced ejection fraction (less than 45%) who are stabilized after a recent decompensation event with IV therapy, also called worsening heart failure event.
  • The German conglomerate said Verquvo is approved in the EU, U.S. Japan, and several other countries.
  • Bayer is jointly developing Verquvo with Merck.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.